Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Sanofi Contingent Value Right (Expiring 12/31/2020) GCVRZ

Healthcare Drug Manufacturers - Major
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Lantus, representing just... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:GCVRZ)

Sanofi Wins Prestigious Drug Discovery Award for Innovative Rare Blood Clotting Disorder Treatment[1]

PR Newswire December 17, 2019

Pomerantz Law Firm Reminds Shareholders With Losses on Their Investment in Sanofi Pharmaceuticals, Inc. of Class Acton Law Suit and Upcoming Deadline -- GCVRZ

GlobeNewswire February 7, 2014

Glancy Binkow & Goldberg Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit on Behalf of Investors of Sanofi Contingent Value Rights

Business Wire February 4, 2014

SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $100,000 in Losses from Investment in Sanofi to Contact Brower Piven Before the February 10, 2014 Lead Plaintiff Deadline

Business Wire January 31, 2014

SANOFI CONTINGENT VALUE RIGHTS SHAREHOLDERS: The Alexander Firm P.C. Announces Upcoming Lead Plaintiff Deadline in Class Action Lawsuit Filed on Behalf of Sanofi Contingent Value Rights Investors

Business Wire January 28, 2014

SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Sanofi Pharmaceuticals, Inc. and Certain Officers - GCVRZ

PR Newswire January 24, 2014

Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit on Behalf of Investors of Sanofi Contingent Value Rights

Business Wire January 17, 2014

Lieff Cabraser Reminds Sanofi Investors of Upcoming Deadline in Class Action Litigation - GCVRZ

Business Wire January 17, 2014

SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $100,000 in Losses from Investment in Sanofi to Contact Brower Piven Before the February 10, 2014 Lead Plaintiff Deadline

Business Wire January 6, 2014
View More News ››

Opinion & Analysis (NDAQ:GCVRZ)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:GCVRZ)

Buehler....buehler....

Anyone care here?
Coloradobuff - August 30, 2019
View more Bullboard ››

Viva Gold Corp.

Viva Gold Corp.

Viva Gold Corp. is a Canada-based gold exploration and development company, The Company’s business is the acquisition ...
View More »